Active-targeted nanotherapy strategies for prostate cancer.

abstract：:Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcin...

journal_title：Current cancer drug targets

authors： Wu J,Di D,Zhao C,Liu Y,Chen H,Gong Y,Zhao X,Chen H

更新日期：2018-01-01 00:00:00

abstract：:The histone deacetylase inhibitors are a new class of cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation and/or apoptosis. Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regula...

journal_title：Current cancer drug targets

authors： Vigushin DM,Coombes RC

更新日期：2004-03-01 00:00:00

abstract：:With increasing incidence of cancer at most of the sites, and growing economic burden and associated psychological and emotional trauma, it is becoming clearer that more efforts are needed for cancer cure. Since most of the chemotherapeutic drugs are non-selective because they are also toxic to the normal cells, new a...

journal_title：Current cancer drug targets

authors： Kaur M,Agarwal R

更新日期：2007-06-01 00:00:00

abstract：:Constitutive activation of the EGFR/RAS/PI3K cell-signaling pathway that may occur through molecular aberrations in core pathway components occurs in many solid tumours, including colorectal cancer(CRC), non-small-cell lung cancer(NSCLC) and breast cancer. Predictive biomarkers of response to therapeutics targeting th...

journal_title：Current cancer drug targets

authors： Barton S,Starling N,Swanton C

更新日期：2010-12-01 00:00:00

abstract：:Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways...

journal_title：Current cancer drug targets

authors： Cai T,Li X,Ding J,Luo W,Li J,Huang C

更新日期：2011-06-01 00:00:00

abstract：:Oncolytic viruses can selectively replicate in and lead to tumor cell lysis with minimal infection/replication potential in adjoining non-neoplastic tissue. Because of paramount safety concerns, first-generation oncolytic viruses were designed to be significantly attenuated in their lytic potential. Results from recen...

journal_title：Current cancer drug targets

authors： Hardcastle J,Kurozumi K,Chiocca EA,Kaur B

更新日期：2007-03-01 00:00:00

abstract：:Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most solid tumors and hematopoietic neoplasms and may be employed as a new...

journal_title：Current cancer drug targets

authors： Gleixner KV,Mayerhofer M,Vales A,Gruze A,Hörmann G,Cerny-Reiterer S,Lackner E,Hadzijusufovic E,Herrmann H,Iyer AK,Krauth MT,Pickl WF,Marian B,Panzer-Grümayer R,Sillaber C,Maeda H,Zielinski C,Valent P

更新日期：2009-08-01 00:00:00

abstract：:Selection of treatment options for clinically localized prostate cancer is based on a host of factors including the patient's age, overall health status, potential complications, clinical tumor stage and Gleason score. It is widely acknowledged that androgen independent disease remains the main obstacle to improving t...

journal_title：Current cancer drug targets

authors： Garrison JB,Kyprianou N

更新日期：2004-02-01 00:00:00

abstract：:Targets for cancer therapy are conventionally selected by identification of molecules acting downstream of established tumour suppressors and oncoproteins, such as p53, c-Myc and Ras. However, the forward genetics approach provides an alternative, conceptually distinct, strategy for identifying target molecules de nov...

journal_title：Current cancer drug targets

authors： Mourtada-Maarabouni M,Watson D,Munir M,Farzaneh F,Williams GT

更新日期：2013-01-01 00:00:00

abstract：:Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways have revolutionized the treatment of patients with metastatic renal cell cancer (RCC). Patients with clear cell RCC often have mutations or silencing of the von Hippel Lindau gene leading to an accumulati...

journal_title：Current cancer drug targets

authors： Heng DY,Bukowski RM

更新日期：2008-12-01 00:00:00

abstract：:Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of ma...

journal_title：Current cancer drug targets

authors： Browne BC,O'Brien N,Duffy MJ,Crown J,O'Donovan N

更新日期：2009-05-01 00:00:00

abstract：:Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell...

journal_title：Current cancer drug targets

authors： Vanamala J,Tarver CC,Murano PS

更新日期：2008-11-01 00:00:00

abstract：:Gastrointestinal (GI) tumors are among the leading cause of death in cancer patients worldwide. Particularly, gastric cancer (GC) is the third cause of cancer deaths, whereas esophageal neoplasm is the eighth leading most common cancer worldwide and its incidence, especially adenocarcinoma type, is continuously increa...

journal_title：Current cancer drug targets

authors： Berretta M,Romano C,Di Francia R,De Diviitis C,Canzonieri V,Caraglia M,Facchini G,Nasti G

更新日期：2018-01-01 00:00:00

abstract：:The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin recept...

journal_title：Current cancer drug targets

authors： Sheldrake HM,Patterson LH

更新日期：2009-06-01 00:00:00

abstract：:Over the past two decades, a number of chemical entities have been investigated in the continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer cells and some have undergone clinical trials, but currently none are in clinical use. Unfortunately, most of these agents suffer clinic...

journal_title：Current cancer drug targets

authors： Mayur YC,Peters GJ,Prasad VV,Lemo C,Sathish NK

更新日期：2009-05-01 00:00:00

abstract：:Polyisoprenylated proteins (PPs) methylation by polyisoprenylated protein methyl transferase (PPMTase) is counteracted by polyisoprenylated methylated protein methyl esterase (PMPMEase). This is the only reversible step of the polyisoprenylation pathway as the relative amounts of the acid and ester forms are determine...

journal_title：Current cancer drug targets

authors： Duverna R,Ablordeppey SY,Lamango NS

更新日期：2010-09-01 00:00:00

abstract：:The efficacy of cancer immunotherapy relies on the ability of the host immune system to recognise the cancer as non-self and eliminate it from the body. Whilst this is an extremely fertile area of medical research, with positive clinical trials showing durable responses, attention must be paid to the subset of patient...

journal_title：Current cancer drug targets

authors： Flower KJ,Ghaem-Maghami S,Brown R

更新日期：2018-01-01 00:00:00

abstract：:Pokemon gene has crucial but versatile functions in cell differentiation, proliferation and tumorigenesis. It is a master regulator of the ARF-HDM2-p53 and Rb-E2F pathways. The facts that the expression of Pokemon is essential for tumor formation and many kinds of tumors over-express the Pokemon gene make it an attrac...

journal_title：Current cancer drug targets

authors： Tian Z,Wang H,Jia Z,Shi J,Tang J,Mao L,Liu H,Deng Y,He Y,Ruan Z,Li J,Wu Y,Ni B

更新日期：2010-12-01 00:00:00

abstract：:The urokinase plasminogen activator (uPA) system (uPAS) consists of the uPA, its cognate receptor (uPAR) and two specific inhibitors, the plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2). The uPA converts the proenzyme plasminogen in the serine protease plasmin, involved in a number of physiopathological proces...

journal_title：Current cancer drug targets

authors： Ulisse S,Baldini E,Sorrenti S,D'Armiento M

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:Cathepsin D (CATD), one of the aspartyl endoproteinase involved in different physiological processes and signaling pathways, is accountable for metabolic breakdown of intracellular proteins, the activation of growth factors, hormones, and precursors of enzyme, the processing of antigens, enzyme inhibitors an...

journal_title：Current cancer drug targets

authors： Dubey V,Luqman S

更新日期：2017-01-01 00:00:00

abstract：:Bid, a BH3-only Bcl-2 family member, is proven to be a pivotal molecule for the regulation of tumorigenesis by its multiple functions in promoting apoptosis, survival and proliferation. Growing evidence supports that Bid has double roles with respect to stress-response. In most cases it functions in a truncated form, ...

journal_title：Current cancer drug targets

authors： Song G,Chen GG,Hu T,Lai PB

更新日期：2010-09-01 00:00:00

abstract：BACKGROUND AND AIM:Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patient...

journal_title：Current cancer drug targets

authors： Santini D,Schiavon G,Vincenzi B,Cass CE,Vasile E,Manazza AD,Catalano V,Baldi GG,Lai R,Rizzo S,Giacobino A,Chiusa L,Caraglia M,Russo A,Mackey J,Falcone A,Tonini G

更新日期：2011-01-01 00:00:00

abstract：:Aberrant expression of the RON receptor tyrosine kinase contributes to breast cancer malignancy. Although clinical trials of RON targeting are underway, the intriguing issue is the diversity of RON expression as evident by cancer cells expressing different variants including oncogenic RON160. The current study determi...

journal_title：Current cancer drug targets

authors： Yao HP,Zhuang CM,Zhou YQ,Zeng JY,Zhang RW,Wang MH

更新日期：2013-07-01 00:00:00

abstract：:The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved ...

journal_title：Current cancer drug targets

authors： Kanodia S,Fahey LM,Kast WM

更新日期：2007-02-01 00:00:00

abstract：:Exosomes are small vesicles that are secreted by various types of cells, known to mediate signal transduction between cells. During recent years, novel carriers for the delivery of targeted drugs, chemotherapy drugs and RNAs are under development, which is believed to be beneficial for patients. Considering issues of ...

journal_title：Current cancer drug targets

authors： Wang X,Zhang H,Yang H,Bai M,Ning T,Li S,Li J,Deng T,Ying G,Ba Y

更新日期：2018-01-01 00:00:00

abstract：:Though modern available cancer therapies are effective, they possess major adverse effects, causing non-compliance to patients. Furthermore, the majority of the polymeric-based medication platforms are certainly not universally acceptable, due to their several restrictions. With this juxtaposition, lipid-based medicat...

journal_title：Current cancer drug targets

authors： Rajpoot K

更新日期：2020-01-01 00:00:00

abstract：:MicroRNAs (miRNAs) control the expression of approximately 60% of protein-coding genes and regulate cell metabolism, proliferation, differentiation, and apoptosis. Notably, aberrant expression of miRNAs contributes to several diseases including cancer. Accumulating evidence indicates that miRNAs play important roles i...

journal_title：Current cancer drug targets

authors： Zheng N,Yang P,Wang Z,Zhou Q

更新日期：2017-01-01 00:00:00

abstract：:The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides its antiviral effect, its potential use in the treatment of cancer has become an important area of research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite CPEC-TP. CPEC-TP is a non c...

journal_title：Current cancer drug targets

authors： Schimmel KJ,Gelderblom H,Guchelaar HJ

更新日期：2007-08-01 00:00:00

abstract：:Mammalian target of rapamycin (mTOR) is a key protein kinase controlling signal transduction from various growth factors and upstream proteins to the level of mRNA translation and ribosome biogenesis, with pivotal regulatory effects on cell cycle progression, cellular proliferation and growth, autophagy and angiogenes...

journal_title：Current cancer drug targets

authors： Ciuffreda L,Di Sanza C,Incani UC,Milella M

更新日期：2010-08-01 00:00:00

abstract：:Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, ...

journal_title：Current cancer drug targets

authors： Liang Z,Lu Z,Zhang Y,Shang D,Li R,Liu L,Zhao Z,Zhang P,Lin Q,Feng C,Zhang Y,Liu P,Tu Z,Liu H

更新日期：2019-01-01 00:00:00